Emergex Demonstrates Excellent Safety Profile for Gold Nanoparticle Used in its Vaccine Platform

  • Gold nanoparticle forms the fundamental basis for all of Emergex’s vaccine constructs
  • These toxicology results help pave the way for a Phase I clinical trial in 2019 of Emergex’s first vaccine candidate targeting Flaviviruses

Oxford, UK, 24 October 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex’s entire infectious disease vaccine platform.

Toxicology studies complying with good laboratory practice (GLP) were successfully completed in standard industry models using Emergex’s gold nanoparticle at a range of doses. No toxicological effects, as measured by key markers, were detected at any level of dosing, confirming the safety of the gold nanoparticle in these models.

The gold nanoparticle forms the central core (or “scaffold”) for immunogenic peptides that together form the final construct for development. The particles can be made to measure less than 5 nanometers in diameter. They act as the carrier system for immunogenic vaccine constructs that comprise synthetic peptides derived from highly conserved components of the disease-causing virus, microbe or pathogen. These peptides have been reverse-engineered using post-infectious blood to identify and select peptides that elicit the strongest cell-mediated immune response. The excellent safety profile demonstrated in these successful preclinical studies now enables Emergex to progress further toxicology testing on viral vaccine constructs in Emergex’s development pipeline and, provided they are successful, first-in-man Phase I safety studies.

Emergex’s first vaccine candidate is scheduled to enter Phase I clinical testing in 2019. It contains immunogenic peptides that are derived from viruses such as Dengue and Zika within the Flavivirus family. The Flavivirus vaccine is designed to universally target this viral genus.

Due to their small size, Emergex’s vaccines can directly enter immune processing cells and trigger cell-mediated immune responses within infected host cells. The small size also enables administration via microneedle patch technology which is less invasive than conventional needle vaccination. Using this administration method the vaccine enters the dermal level of the skin, which then directly stimulates the immune system. Emergex’s vaccine technology can also be applied for the development of vaccines for other pathogenic microbes such as antibiotic resistant bacteria.

Laurens Rademacher, Emergex’s Chief Technology Officer commented: “These results are a significant milestone as we advance towards clinical development of our Flavivirus vaccine. The excellent safety profile that we have seen on our base gold nanoparticle in these preclinical studies provides us with renewed confidence in a significant part of the contributing technology. We therefore expect the regulatory process for the upcoming clinical phases to be attainable within our anticipated timelines, ensuring that we remain on course to achieve our vision of providing vaccines that are effective, affordable and safe.”

Emergex’s business model is to create International Vaccine Repositories of post Phase I vaccines that act as a first-line of defense against existing, emerging and emergency infectious outbreaks and that will be subscribed to by governments, non-governmental organisations and/or charities. Access to these are repository is expected to provide Emergex with initial revenues.

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited

Emergex Vaccines Holding Limited (“Emergex”), a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats including Flaviviruses, such as Dengue Fever and Zika as well as Filoviruses, such as Ebola and Marburg viruses, and seasonal and pandemic influenza.

The Company has developed a novel and ground-breaking approach to vaccine manufacturing. It utilises 100% synthetic components that have been validated in previous research, to activate T-cells of the immune system to destroy infected human cells. It uses unique technologies together with scientific insights to develop and manufacture vaccines at a fraction of the time and cost of conventional vaccines. These are administered using a skin patch technology which is practical to administer and suited to regions that are infrastructurally-challenged as well as for more advanced regions of the world.

Emergex is initially focussed on creating an internationally accessible, clinical-grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Emergex is a member of the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

Find out more online at www.emergexvaccines.com.

Media Contacts:

Instinctif Partners

Sue Charles / Ashley Tapp

Phone: +44 (0)20 7457 2020

Email: emergex@instinctif.com

 

Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases

Oxford, UK, 20 September 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.

The MoU consists of three parts. The first part is a Collaboration Agreement under which Fiocruz and Emergex will initially carry out a Phase I clinical trial to demonstrate flavivirus vaccine safety. Thereafter, the two parties expect to carry out further clinical studies to test the vaccine in the field. The second part of the MoU is an ‘umbrella’ R&D agreement under which Emergex and Fiocruz will co-develop vaccines to viruses that are of specific importance to the Brazilian government and are prevalent and endemic in the region. Emergex and Fiocruz will develop vaccines collaboratively to find solutions for various diseases that have not yet been resolved using conventional vaccine approaches. The third part of the MoU covers a vaccine technology transfer agreement for vaccines that will be used within Brazil’s National Health Service.

Emergex’s vaccines are 100% synthetic, multi-component vaccines containing peptides that are highly conserved between viral strains. This means that Emergex can create a “universal” vaccine that is cross-reactive and targets numerous diseases within one viral family. One example of this is Emergex’s universal flavivirus vaccine which is designed to target diseases such as Dengue Fever, Zika and Yellow Fever.

Professor Thomas Rademacher, co-founder, CEO and CSO at Emergex commented: “Fiocruz is recognized as one of the world’s largest public health research institutions. It has a broad range of responsibilities related to the health and wellbeing of the Brazilian population of over 207 million people. The signing of this MoU is a commitment to explore how our organizations can work together to develop new vaccines against major viral threats that occur in the region.”

Marco Krieger, VP Production and Innovation at Fiocruz added: “Fiocruz is committed to researching, developing and manufacturing new vaccines to address Brazil’s most important infectious diseases. This MoU demonstrates our intention to partner with Emergex to develop a new generation of vaccines. We chose Emergex as its technology enables it to develop and manufacture vaccines in less time and at a fraction of the cost of traditional vaccines. Its vaccine components are stable at ambient temperatures, avoiding the need for refrigeration, reducing costs and enabling easy transportation – making it particularly suited to treating diseases in remote parts of the world.”

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited

Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, reverse engineering the immune system and providing that system with data that alters the viral factory. It utilises 100% synthetic components that have been validated in previous research, to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with cleverly crafted scientific capability to develop and manufacture vaccines at a fraction of the time and cost of conventional vaccines, administered practicably for regions that are infrastructurally-challenged in the developing world as well as for the developed world.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also is strategically open to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Recently it joined the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

Find out more online at www.emergexvaccines.com.

 

About Fundação Oswaldo Cruz (Oswaldo Cruz Foundation, known as Fiocruz)

Inaugurated on May 25, 1900 under the name The Federal SeroTherapy Institute, Fiocruz’s mission was to fight public health problems in Brazil. Since then it has developed and become a leading think tank concerned with Brazilian experimental medicine.

Concepts that have guided Fiocruz’s development include the promotion of health and social development, forging and disseminating scientific and technological knowledge, and promoting the benefits of Brazilian citizenship.

Today, Fiocruz is attached to the Brazilian Ministry of Health and is the most prominent science and technology health institution in Latin America. It is responsible for a range of activities which include research development; highly-regarded hospital and ambulatory care services; production of vaccines, drugs, reagents, and diagnostic kits; education and training of human resources; information and communication in the area of health, science and technology; quality control of products and services, and the implementation of social programs. It has over 7,500 employees and health professionals.

For more information, please visit the Fiocruz website.

Media Contacts:

Instinctif Partners

Sue Charles / Ashley Tapp

Phone: +44 (0)20 7457 2020

Email: Emergex@instinctif.com

 

Emergex Appoints US Federal Government Experts The Conafay Group

Oxford, UK, 13 July 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has appointed The Conafay Group, US Federal Government experts, to advise on the US healthcare landscape and policy and to provide introductions to help establish new business contacts.

Emergex’s business model is initially focused on creating an International Vaccine Repository of post Phase I vaccines, for subscription by governments, non-governmental organisations and charities to act as a first line of defence against existing and newly emerging infectious outbreaks. Emergex’s partnership with The Conafay Group will help them achieve this goal.

The Conafay Group is experienced at providing companies with a unique insights into the US non-dilutive and federal funding landscape, healthcare and innovation policy, federal government needs and priorities, and commercial/institutional partnering opportunities.

Stephen Conafay, founder at Conafay Group commented: “The Conafay Group is proud to partner with Emergex Vaccines to assist in bringing a unique approach to U.S. stakeholders”, said Stephen Conafay, Principal. “By strategically developing a comprehensive approach to engage with the U.S. federal government, we look forward to helping Emergex Vaccines advance solutions through the pipeline and closer to patients around the world.”

Professor Thomas Rademacher, co-founder, CEO and CSO at Emergex commented: “We are looking forward to working closely with The Conafay Group as we continue to progress our vaccines to Phase I. The Conafay Group’s expertise will provide us with new tools and contacts to progress our vision and get our vaccines to patients who really need them.”

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited

Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Recently it joined the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

Find out more online at www.emergexvaccines.com.

 

About Conafay Group LLC

The Conafay Group works with life science companies and organizations to develop and implement government funding and public policy strategies.  We also bridge ties to philanthropic, non-profit, academic and commercial entities to enhance client outcomes.  TCG specializes in representing biomedical technologies and therapeutics before the federal government and associated stakeholders. Our client successes involve for-profit and non-profit entities in areas of funding, research and public policy. We identify and target novel funding opportunities, synergies between client technology and federal/private needs, and policy issues that affect life sciences companies. Our expertise provides our clients an advantage over competitors in the federal and non-federal funding market.

Led by Stephen Conafay, The Conafay Group is an assembled team of scientists and policy experts, as well as former industry executives and federal staff, that offers a wealth of scientific and policy expertise in issues relevant to the life sciences and biotechnology industry. Applying this collective expertise, we have an intimate understanding of the non-dilutive funding landscape, healthcare and innovation policy, federal government needs and priorities, and commercial/institutional partnering opportunities. Our strength lies in putting this knowledge, and our familiarity with the science behind our clients’ technology, to work for our clients. Through our team‐based approach, we can deliver fully integrated government relations strategies that enable our clients to achieve greater success.

 

For more information, visit: www.conafaygroup.com

 

Media Contacts:

Instinctif Partners

Sue Charles / Ashley Tapp

Phone: +44 (0)20 7457 2020

Email: Emergex@instinctif.com

Emergex Files a Patent in the USA for its novel Pandemic Flu Vaccine

Oxford, UK, 24 May 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to enable synthetic vaccine development in the field of infectious diseases, today announces that it has filed a patent in the USA for its novel pandemic flu vaccine.

The patent, entitled, ‘Reverse Peptide Vaccines’ covers the use of peptides derived from human influenza A, the most frequent influenza serotype and the cause of most major flu outbreaks.

The first recognized flu pandemic was in the summer of 1510 and there have been 15 flu pandemics over the last 500 years1. Following the 1918 Spanish flu and despite the introduction of flu vaccines in the 1940s four further flu pandemics have occurred2. Flu pandemics have always been preceded by flu outbreaks in animals which resulted in the introduction of a viral strain into the human population in which no herd immunity existed and human-to-human transmission was possible. These pandemic characteristics make the use of universal flu vaccines based on current circulating flu strains problematic for the prevention of novel pandemic flu strains entering the human population.

The conserved human HLA-associated peptide fragments covered by this patent are unexpectedly coded by a non-coding strand of RNA conserved in all current human influenza A viruses, including the strain that caused the 1918 ‘Spanish flu’.

As these conserved HLA-associated peptide fragments are present in all human influenza A viruses, it suggests that they play a vital role in human-to-human viral transmission, a key requirement for the establishment of a new flu pandemic derived from circulating animal flu viruses. Mutation of current circulating non-human influenza A viruses and mutations enabling the machinery for the generation of these human HLA-associated peptide fragments could have a serious implication in causing a future human flu pandemic.

Professor Thomas Rademacher, co-founder, CEO and CSO at Emergex commented: “There is an urgent need for novel and innovative solutions that address the threat of a new global flu pandemic. We believe that our synthetic vaccines, combining several cutting-edge technologies could provide a solution.”

Emergex’s synthetic T-cell stimulating influenza vaccines incorporating these human and potentially pandemic-specific targets are currently in pre-clinical testing. On 14 May, Emergex announced that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.

In addition to developing its flu vaccine, Emergex is also developing a universal Flavivirus vaccine which is cross reactive against Zika, Dengue and Yellow Fever, and a universal Filovirus vaccine which is cross reactive against Ebola and Marburg virus.

References

  1. Pandemic Influenza’s 500th Anniversary. Clinical Infectious Diseases, Volume 51, Issue 12, 15 December 2010, Pages 1442–1444, https://doi.org/10.1086/657429
  2. Influenza Pandemics of the 20th Century. Emerg Infect Dis. 2006 Jan; 12(1): 9–14. doi: https://dx.doi.org/10.3201%2Feid1201.051254

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited

Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Recently it joined the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

Find out more online at www.emergexvaccines.com.

 

Media Contacts:

Instinctif Partners

Sue Charles / Ashley Tapp

Phone: +44 (0)20 7457 2020

Email: Emergex@instinctif.com

Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine

Oxford, UK, 14 May 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.

This grant will cover 70% of the cost of developing Emergex’s flu vaccine programme over a period of two years. It will be used to complete preclinical toxicology and validation studies and the manufacturing of the vaccine in accordance with current Good Manufacturing Practice (cGMP). This will result in clinical batches of the vaccine which are ready for Phase I clinical testing in the first half of 2020.

Emergex’s universal flu vaccine is designed to target components of the influenza virus that are common to all influenza strains. As a result this vaccine will also be suitable to target the outbreak of a new flu pandemic caused by the emergence of a novel form of influenza virus at the time it moves from an animal species into humans. The company’s vaccine is 100% synthetic and delivers highly conserved immunogenic peptide fragments from the flu virus to antigen presenting cells in the skin, eliciting a strong and long-lasting T-cell immune response.

Emergex’s vaccine combines several proprietary technologies to create an immune response based on ‘reverse engineering’. This involves the identification of highly conserved internal peptide fragments from the flu virus, synthesis of these peptide fragments to create a library of 100% synthetic peptide fragments and screening these against blood from flu survivors to see which of the fragments elicit the strongest T-cell immune response. The selected peptide fragments are then combined with a gold nanotechnology carrier system to make an extremely small particle, less than 5 nanometres in diameter, which is ideal for immunization through the skin using a microneedle skin patch, which is less invasive than traditional injection.

The UK government risk register has identified pandemic flu as one of one of the most severe natural challenges likely to affect the UK over the next few years1. A recent World Health Organization model predicts that pandemic flu could kill an estimated 720,000 people per year and result in economic losses of over US$500bn2.

Professor Thomas Rademacher, co-founder, CEO and CSO at Emergex commented, “This Innovate UK grant provides endorsement of our flu vaccine programme and reinforces our belief that an innovative approach, using the very latest technologies, could help protect the public from this inevitable epidemic or pandemic health threat.”

In addition to developing a universal flu vaccine, Emergex is also developing a universal Flavivirus vaccine which is cross reactive against Zika, Dengue and Yellow Fever, and a universal Filovirus vaccine which is cross reactive against Ebola and Marburg virus.

References

  1. UK National Risk Register https://www.scribd.com/document/4746228/UK-National-Risk-Register
  2. How large are the expected losses? Bulletin of the World Health Organization 2018;96:129-134. doi: http://www.who.int/bulletin/volumes/96/2/17-199588/en/

-Ends-

 

Notes to Editors

About Emergex Vaccines Holding Limited

Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Recently it joined the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

Find out more online at www.emergexvaccines.com.

About Innovate UK

Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. Find out more online at www.innovateuk.gov.uk.

Media Contacts:

Instinctif Partners

Sue Charles / Ashley Tapp

Phone: +44 (0) 20 7457 2020

Email: Emergex@instinctif.com 

Sir David King Joins Emergex’s Board of Directors

Oxford, UK, 29 March 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Sir David King has joined Emergex’s Board as a Non-Executive Director.

David is an Affiliate Partner of SYSTEMIQ, the corporate and government sustainability advisory firm and has held a number of international positions in senior government roles over the last 18 years.

Professor Thomas Rademacher, co-founder, CEO and CSO at Emergex commented, “Our business model is initially focused on creating an International Vaccine Repository of post Phase I vaccines, for subscription by governments, non-governmental organisations and charities to act as a first line of defense against existing and newly emerging infectious outbreaks. Sir David King brings a wealth of international experience and access to government and industry contacts, which will be invaluable to us as we start to commercialise our vaccines.”

Sir David King, Partner of SYSTEMIQ, commented, “When you consider the devastating effects on human health and life caused by disease outbreaks such as Zika, Ebola and Influenza, it becomes obvious that we must do everything we can to combat these infectious diseases. Emergex’s portfolio of vaccines, which are designed to provide long-lasting immunity, to be easily administered as well as rapidly and cost-effectively produced, could have an immense impact worldwide against existing and newly emerging infectious disease outbreaks.”

Most recently, from 2013 – 2017, David was the UK Government Foreign Secretary’s Special Representative on Climate Change, working with 165 Climate Change Attachés in UK Embassies.

From 2012 – 2016 David was the UK Government Chief Scientific Adviser, raising awareness of the need for governments to act on climate change. He was instrumental in creating the Energy Technologies Institute, a public-private partnership between global energy and engineering companies and the UK Government. He also created an in-depth Futures process which advised Government on a wide range of long-term issues, ranging from flooding to obesity.

In addition to his roles in Government, David has also had a distinguished academic career. He attended Witwatersrand University in South Africa, graduating in Chemistry and later obtaining a PhD. David has subsequently received 23 Honorary Degrees from universities around the world. David was Head of the Department of Chemistry and the Master of Downing College at the University of Cambridge. Over the course of his academic career, David has published over 500 papers on surface science and catalysis and on science and policy.

David was elected Fellow of the Royal Society in 1991 and was a Foreign Fellow of the American Academy of Arts and Sciences in 2002. He was knighted in 2003 and was made “Officier dans l’ordre national de la Légion d’Honeur” by the President of France in 2009.

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited

Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Recently it joined the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

Find out more online at www.emergexvaccines.com.

Media Contacts:

Instinctif Partners

Sue Charles /Ashley Tapp

Phone: +44 (0)20 7457 2020

Email: Emergex@instinctif.com

Emergex Builds its Finance Team with Two New Recruits

Oxford, UK, 28 March 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has built its Finance team and strengthening its operational capabilities.

Alex Bronimann joins Emergex as Finance Director. He brings over 20 years’ experience in the healthcare, pharmaceutical, technology, telecoms and manufacturing sectors. Alex’s strengths will contribute to financial strategy, focusing on financing activities, global costing, pricing and oversight of the Company’s finances. He leads day-to-day responsibility for financial controls and reporting, budgeting, forecasting, audit, tax, cash and treasury management.

Prior to Emergex, Alex was Finance Director at OrganOx Ltd, an Oxford University spin-out and start-up medical device company. Previously, Alex was Group CFO and Board Director at Adestra Group and before that he worked for several ‘blue chip’ companies including Vodafone, GE, Dell, Amersham and Cable & Wireless. Alex is a qualified Chartered Accountant.

Natalie Sands also joins Emergex’s new Finance function as Financial Controller. She is responsible for day-to-day financial operations including management reporting, payroll, supporting the audit process, and establishing robust financial policies and procedures.

Natalie has a broad range of experience in commercial finance including at large companies such as Live Nation Entertainment Ltd and Amey Plc. She joins Emergex from Amey Plc, where she was Senior Accountant within the Investments division, which included complex accounting for Special Purpose Vehicle Companies (SPV). Prior to this she was Group Financial Controller for Summit Therapeutics Plc. Natalie is a qualified Chartered Certified Accountant and is a Fellow member of the Association of Chartered Certified Accountants.

Professor Thomas Rademacher, co-founder, CEO and CSO at Emergex commented, “Alex and Natalie join Emergex at an exciting time in our growth as we look to advance the development of EMX-001, our universal Flavivirus vaccine candidate, for diseases such as Zika, Dengue and Yellow Fever towards clinical development early next year and our universal Filovirus and Influenza programmes in preclinical development. The new capabilities that Alex and Natalie bring will help support fundraising and ensure that we establish strong financial governance and cost controls as we grow.”

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited

Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Recently it joined the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

Find out more online at www.emergexvaccines.com.

Media Contacts:

Instinctif Partners
Sue Charles/ Ashley Tapp
Phone: +44 (0)20 7457 2020
Email: Emergex@instinctif.com

Emergex Progresses its Synthetic Vaccine Development Pipeline

  • Pioneering a simple, inexpensive and fast approach to vaccine development using 100% synthetic vaccine constructs to provide long-lasting cellular immunity against infections
  • Lead vaccine candidates have been identified for our universal Flavivirus (Dengue, Zika, Yellow Fever), universal Filovirus (Ebola) and Pandemic/universal Influenza virus programmes
  • Dengue, Ebola and Zika vaccines are all approaching clinical development, with Phase I trials due to start in Q1 2019

Oxford, UK, 26 March 2018 – Emergex Vaccines Holding Limited (“Emergex”), a private biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today provides an update on its vaccine development pipeline and business.

Emergex was established in January 2016 with the primary focus of developing 100% synthetic vaccines, designed to elicit a cytotoxic T-cell response and long lasting immunity against existing and emerging viral and bacterial infections.

Professor Thomas Rademacher, co-founder, CEO and CSO at Emergex commented, “Vaccine development has historically been perceived as a timely, costly and difficult process which often has produced disappointing results. Our unique technologies enable us to create vaccines in a timely manner, utilizing a very simple synthesis process that results in vaccines that are a fraction of the price of conventional vaccines. We believe that these vaccines could make a difference to people afflicted by some of the most serious infectious diseases in the world today. We have completed some important milestones for our lead vaccine candidates in each of the viral families that will lead to clinical validation early next year.”

Pipeline Update

Emergex’s vaccines combine synthetic peptide constructs representing highly conserved components of a virus family with a gold nanoparticle carrier system. Immunogenic peptide-gold nanoparticles that elicit the strongest cell-mediated immune response are reverse-engineered to work in disparate genetic populations following identification and selection using post-infectious blood assays. The final vaccine constructs are designed to elicit a cytotoxic T cell  immune response similar to that which would occur naturally in individuals of any Human Leukocyte Antigen (HLA)* type who were exposed and then successfully recovered from an infection.

During 2017 and early 2018 vaccine constructs for Emergex’s Flavivirus, Filovirus and Influenza virus development programmes were successfully synthesized using exclusively licensed technology.

Emergex has specifically designed and developed to cGMP-like quality the fundamental gold nanoparticle that will act as the standard core for all of its vaccines. This particle has the advantage of strong inherent immunogenicity and is easy to synthesise on its own and as a component in peptide-based vaccine constructs. The particle has entered toxicology testing with results due towards the end of the year.

Emergex’s lead development programme is a strain cross reactive Dengue (Flavivirus) vaccine candidate incorporating peptides that also target other Flaviviruses such as Zika and Yellow Fever. A single Flavivirus indication will initially be tested through to Phase I and will set the regulatory pathway standard.  A Phase I clinical trial is expected to commence early next year.

The Company also has programmes in parallel development for a universal Filovirus vaccine, to target Ebola, and for a pandemic flu vaccine.

Advantages of Emergex Vaccines

Emergex’s synthetic vaccines provide significant advantages when compared to traditional vaccines. They stimulate cell-mediated immunity, resulting in preventative and therapeutic effects and can be developed in less time and at a fraction of the cost of traditional vaccines. The vaccines are administered via a micro-needle patch to support reasonable compliance rates and in addition, stability at ambient temperatures, enabling easy shipping and convenient distribution, particularly as some developing nations are subject to poor infrastructure.

Business Update

Emergex’s technologies and capabilities have already attracted the attention of Governments, Health Authorities and Academic Institutions around the world and advanced discussions are underway in South America, Asia and Africa with the aim of addressing some of their most urgent healthcare challenges. Emergex’s vaccines will initially be marketed to Vaccine Repositories in order to be available for distribution at the time of an epidemic outbreak.

* The human leukocyte antigen (HLA) system or complex is a gene complex encoding the major histocompatibility complex (MHC) proteins in humans.

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited
Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a unique approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses synergistic technologies together with new insights into immune surveillance to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. It is a member of the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

Find out more online at www.emergexvaccines.com.

Media Contacts:

Instinctif Partners
Sue Charles / Ashley Tapp
Phone: +44 (0)20 7457 2020
Email: Emergex@instinctif.com

 

Emergex Vaccines awarded SBRI contract by Innovate UK

Oxford, UK, 5 April 2017 – Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that they have been awarded a £499,825 SBRI contract with the Department of Health/Technology Strategy Board, facilitated by Innovate UK, the UK’s Innovation Agency. The ‘Vaccines for Global Development – Preclinical’ grant proceeds will be used to advance the Zika and multivalent filovirus (Ebola and Marburg) vaccine programmes.

Professor Thomas Rademacher, CEO, commented “Emergex has a grand vision to create a socially responsible company that will address the critical global need to have affordable and effective vaccines against emerging viral and bacterial outbreaks. By creating an International Repository of vaccines that can be used at the start of epidemics, we can potentially protect populations at the time of utmost need. This will also allow for field testing of human-specific T cell vaccines in relevant clinical situations. The support from Innovate UK will allow us to advance our Zika and Filovirus vaccine programmes as quickly as possible.

For more detail on the award, please see the Innovate UK announcement of the competition results (Pg. 11) here.

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited
Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Recently it joined the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

Find out more online at www.emergexvaccines.com.

Media Contacts:

Instinctif Partners
Sue Charles/Eileen Paul//Ashley Tapp/Emma-Jane Humphreys
Phone: +44 (0)20 7457 2020
Email: Emergex@instinctif.com

Emergex Vaccines approved as member of the Social Stock Exchange

Oxford, UK, 20 February 2017 – Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announces that they have been approved as a member of the Social Stock Exchange, society’s market for impact investing. This follows the ratification of Emergex’s impact report by the Social Stock Exchange’s independent Admissions Panel.

Emergex aim to offer a novel approach to vaccine development, using 100% synthetic components to activate the immune system; this technology is ideally suited to low resource environments such as the developing world, which are disproportionately affected by pandemics caused by these types of diseases. These vaccines will be used to create a clinical grade international vaccine repository that will act as a first line of defence against existing and newly emerging infectious outbreaks.

The Social Stock Exchange enables its accredited impact issuers to raise capital or undertake primary or secondary listings of debt or equity instruments.

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited
Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity.

Find out more online at www.emergexvaccines.com.

About the Social Stock Exchange
The Social Stock Exchange provides access to the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities. The aim of the exchange is to help these businesses connect with investors and unlock capital at scale. All issuer member companies must meet a rigorous set of criteria before joining, including the publication of an Impact Report.

The Social Stock Exchange has an agreement with NEX Exchange (formerly ISDX) to operate the Social Stock Exchange branded market segment for impact businesses.

The Social Stock Exchange Ltd (FRN: 625231) is an appointed representative of Kession Capital Limited (FRN: 582160) which is authorised and regulated by the Financial Conduct Authority (“FCA”) in the UK.
NEX is a Recognised Investment Exchange operating a regulated market and a growth market and provides a secondary market trading facility. NEX is supervised by the FCA.

For more information, please visit www.socialstockexchange.com.

Media Contacts:

Instinctif Partners
Sue Charles/Eileen Paul//Ashley Tapp/Emma-Jane Humphreys
Phone: +44 (0)20 7457 2020
Email: Emergex@instinctif.com